FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Julio Montaner

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Procedures

Geographic Areas

Living Beings

HIV-1

Concepts & Ideas

Activities & Behaviors

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Kenneth Mayer; Sheena McCormack; Julio S G Montaner; Helen Rees; Bruce Schackman; José M Zuniga; K Rivet Amico; Jane Anderson; Yusef Azad; Gus Cairns; Nikos Dedes; Chris Duncombe; Sarah J Fidler; Brian Gazzard; Reuben Granich; Michael A Horberg; Papa Salif Sow
Controlling the HIV Epidemic with Antiretrovirals: IAPAC Consensus Statement on Treatment as Prevention and Preexposure Prophylaxis.
Bojan Ramadanovic; Julio S G Montaner; Ali Nadaf; Krisztina Vasarhelyi; Ralf W Wittenberg; Evan Wood; Alexander R Rutherford
Changing Risk Behaviours and the HIV Epidemic: A Mathematical Analysis in the Context of Treatment as Prevention.
Bohdan Nosyk; Benita Yip; Keith Chan; Guillaume Colley; Mark Gilbert; P Richard Harrigan; Katherine Heath; Robert S Hogg; Viviane D Lima; Julio S G Montaner
Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Julio Montaner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kenneth Mayer; Sheena McCormack; Julio S G Montaner; Helen Rees; Bruce Schackman; José M Zuniga; K Rivet Amico; Jane Anderson; Yusef Azad; Gus Cairns; Nikos Dedes; Chris Duncombe; Sarah J Fidler; Brian Gazzard; Reuben Granich; Michael A Horberg; Papa Salif Sow
Controlling the HIV Epidemic with Antiretrovirals: IAPAC Consensus Statement on Treatment as Prevention and Preexposure Prophylaxis.
Journal of the International Association of Providers of AIDS Care 2013;12(3):208-16.
2013: Bojan Ramadanovic; Julio S G Montaner; Ali Nadaf; Krisztina Vasarhelyi; Ralf W Wittenberg; Evan Wood; Alexander R Rutherford
Changing Risk Behaviours and the HIV Epidemic: A Mathematical Analysis in the Context of Treatment as Prevention.
PloS one 2013;8(5):e62321.
2013: Bohdan Nosyk; Benita Yip; Keith Chan; Guillaume Colley; Mark Gilbert; P Richard Harrigan; Katherine Heath; Robert S Hogg; Viviane D Lima; Julio S G Montaner
Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada.
PloS one 2013;8(1):e54416.
2013: Despina Tzemis; Wendy Zhang; Kimberly A Fernades; Jamie I Forrest; Colin W McInnes; Julio S G Montaner; Treena R Orchard; Alexis K Palmer; Cathy M Puskas; Robert S Hogg
Identifying self-perceived HIV-related stigma in a population accessing antiretroviral therapy.
AIDS care 2013;25(1):95-102.
2012: Evan Wood; Julio S G Montaner
Guidelines for persons with HIV.
Annals of internal medicine 2012;157(11):832-3; author reply 833-4.
2012: Michael V O'Shaughnessy; Steffanie A Strathdee; Robert S Hogg; Julio S G Montaner
Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver.
Current HIV/AIDS reports 2012;9(4):394-400.
2012: Hatoon M Ezzat; Marianne Harris; Lisa K Hicks; Jordana Boro; Matthew C Cheung; Viviane D Lima; Julio S G Montaner; Heather A Leitch
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Leukemia & lymphoma 2012;53(12):2390-6.
2012: Mark W Hull; Zunyou Wu; Julio S G Montaner
Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention.
Current opinion in HIV and AIDS 2012;7(6):579-86.
2012: Julio S G Montaner
[Adverse consequences for the human immunodeficiency virus epidemic in Spain following the new legal health framework on the illegal immigrants - save today and pay more tomorrow].
Enfermedades infecciosas y microbiología clínica 2012;30(8):431-2.
2012: Viviane D Lima; Keith Chan; Tsubasa Kozai; Bohdan Nosyk; Evan Wood; Wendy Zhang; Julio S G Montaner
Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
AIDS (London, England) 2012;26(12):1491-500.
2012: Sam M Wiseman; Benita Yip; Wendy Zhang; Joe E Chan; Jamie I Forrest; Robert S Hogg; Viviane D Lima; Julio S G Montaner
Factors predictive of 30-day postoperative mortality in HIV/AIDS patients in the era of highly active antiretroviral therapy.
Annals of surgery 2012;256(1):170-6.
2012: Thomas Kerr; Brandon D L Marshall; M-J Milloy; Julio S G Montaner; Silvia Guillemi; Ruth Zhang; Evan Wood
Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.
Drug and alcohol dependence 2012;124(1-2):108-12.
2012: J Troy Grennan; P Richard Harrigan; Bob Hogg; Marina Klein; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Janet Raboud; Sean B Rourke; DeSheng Su; Christos Tsoukas; Curtis Cooper
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.
The Journal of infectious diseases 2012;205(8):1230-8.
2012: Conar R O'Neil; Alexis K Palmer; Anya Shen; Wendy Zhang; Suzy Coulter; Julio S G Montaner; Nadia O'Brien; Robert S Hogg
Factors Associated with Antiretroviral Medication Adherence among HIV-Positive Adults Accessing Highly Active Antiretroviral Therapy (HAART) in British Columbia, Canada.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2012;11(2):134-41.
2012: Evan Wood; Michael John Milloy; Julio S G Montaner
HIV treatment as prevention among injection drug users.
Current opinion in HIV and AIDS 2012;7(2):151-6.
2012: Bohdan Nosyk; Julio S G Montaner
The evolving landscape of the economics of HIV treatment and prevention.
PLoS medicine 2012;9(2):e1001174.
2012: Xuetao Wang; Wen Zhang; Robert S Hogg; Lawrence McCandless; Deborah Money; Julio S G Montaner; Neora Pick; Kate A Salters; Angela Kaida
Women's Health Care Utilization among Harder-to-Reach HIV-Infected Women ever on Antiretroviral Therapy in British Columbia.
AIDS research and treatment 2012;2012():560361.
2012: Robert S Hogg; Steve Kanters; Thomas Kerr; Viviane D Lima; Bohdan Nosyk; Evan Wood; Katherine Heath; Julio S G Montaner
Disparities in the burden of HIV/AIDS in Canada.
PloS one 2012;7(11):e47260.
2012: Viviane D Lima; Bohdan Nosyk; Benita Yip; Rolando Barrios; P Richard Harrigan; Robert S Hogg; Adrian Le; Julio S G Montaner
Development and validation of a composite programmatic assessment tool for HIV therapy.
PloS one 2012;7(11):e47859.
2012: Chanson J Brumme; Viviane D Lima; Julio S G Montaner; Stuart Skinner; Luke C Swenson; Brian Wynhoven; Benita Yip; P Richard Harrigan
Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay.
PloS one 2012;7(8):e43882.
2012: Wendy Zhang; Jamie I Forrest; Robert S Hogg; Julio S G Montaner; Nadia O'Brien; Thomas L Patterson; Kate A Salters; Viviane D Lima
Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada.
PloS one 2012;7(7):e40793.
2012: Kimberley L S Ambler; Viviane Dias Lima; Lynda M Foltz; Marianne Harris; Chantal Leger; Julio S G Montaner; Linda M Vickars; Heather A Leitch
Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era.
Advances in hematology 2012;2012():910954.
2011: Surita Parashar; Anya Shen; Keith Chan; Suzy Coulter; Julio S G Montaner; Nadia O'Brien; Alexis K Palmer; Robert S Hogg
Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed.
AIDS and behavior 2011;15(8):1612-22.
2011: Alexis K Palmer; Despina Tzemis; Wendy Zhang; Beza Ayalew; Katrina C Duncan; V Lima; Julio S G Montaner; Robert S Hogg
"The way I see it": the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada.
AIDS care 2011;23(11):1456-66.
2011: K N Deering; Julio S G Montaner; Jean A Shoveller; Mark W Tyndall; Kate Shannon
The street cost of drugs and drug use patterns: relationships with sex work income in an urban Canadian setting.
Drug and alcohol dependence 2011;118(2-3):430-6.
2011: Kate Shannon; Ruth Zhang; Aranka Anema; Thomas Kerr; M-J Milloy; Julio S G Montaner; Evan Wood
Severe food insecurity is associated with elevated unprotected sex among HIV-seropositive injection drug users independent of HAART use.
AIDS (London, England) 2011;25(16):2037-42.
2011: Mark W Hull; Julio S G Montaner
Optimizing initial therapy for HIV infection.
The Journal of infectious diseases 2011;204(8):1154-6.
2011: Dan Werb; Kora Debeck; Thomas Kerr; Edward J Mills; Julio S G Montaner; Evan Wood
The effectiveness of anti-illicit-drug public-service announcements: a systematic review and meta-analysis.
Journal of epidemiology and community health 2011;65(10):834-40.
2011: Andrew D Revell; Dechao Wang; Mark A Boyd; Frank De Wolf; Sean Emery; Richard Harrigan; Clifford Lane; Brendan A Larder; Julio S G Montaner; Anton L Pozniak
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.
AIDS (London, England) 2011;25(15):1855-63.
2011: Darrell H S Tan; Chris Tsoukas; Sharon Walmsley; Keith Chan; Curtis Cooper; Robert S Hogg; Marina B Klein; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Janet Raboud; Sean B Rourke
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Journal of acquired immune deficiency syndromes (1999) 2011;58(1):38-46.
2011: Mark W Hull; Julio S G Montaner
Ritonavir-boosted protease inhibitors in HIV therapy.
Annals of medicine 2011;43(5):375-88.
2011: Seonaid Nolan; Ruth Zhang; Robert S Hogg; Thomas Kerr; M-J Milloy; Julio S G Montaner; Evan Wood
Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
AIDS care 2011;23(8):980-7.
2011: Julio S G Montaner
Treatment as prevention--a double hat-trick.
Lancet 2011;378(9787):208-9.
2011: Laura Kuyper; M-J Milloy; Brandon D L Marshall; Ruth Zhang; Thomas Kerr; Julio S G Montaner; Evan Wood
Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?
Addictive behaviors 2011;36(5):560-3.
2011: Brandon D L Marshall; M-J Milloy; Evan Wood; Julio S G Montaner; Thomas Kerr
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study.
Lancet 2011;377(9775):1429-37.
2011: Krisztina Vasarhelyi; Eirikka K Brandson; Alexis K Palmer; Kimberly A Fernandes; Wendy Zhang; David M Moore; Julio S G Montaner; Hogg Robert
Home is where the HAART is: an examination of factors affecting neighbourhood perceptions among people with HIV/AIDS on antiretroviral therapy.
AIDS care 2011;23(2):245-51.
2011: Luke C Swenson; Graham Pollock; Brian Wynhoven; Theresa Mo; Winnie Dong; Hogg Robert; Julio S G Montaner; P Richard Harrigan
"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
PloS one 2011;6(2):e17402.
2011: O Eyawo; K A Fernandes; E K Brandson; A Palmer; K Chan; Viviane D Lima; R P Harrigan; Julio S G Montaner; Hogg Robert
Suboptimal use of HIV drug resistance testing in a universal health-care setting.
AIDS care 2011;23(1):42-51.
2011: Brandon D L Marshall; Evan Wood; Jean A Shoveller; Thomas L Patterson; Julio S G Montaner; Thomas Kerr
Pathways to HIV risk and vulnerability among lesbian, gay, bisexual, and transgendered methamphetamine users: a multi-cohort gender-based analysis.
BMC public health 2011;11():20.
2011: Melanie C M Murray; Rolando Barrios; Wendy Zhang; Mark Hull; Valentina Montessori; Hogg Robert; Julio S G Montaner
Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic.
European journal of gastroenterology & hepatology 2011;23(1):45-50.
2011: Katrina C Duncan; Charlotte Reading; Alexandra M Borwein; Melanie C M Murray; Alexis Palmer; Warren Michelow; Hasina Samji; Viviane D Lima; Julio S G Montaner; Hogg Robert
HIV incidence and prevalence among aboriginal peoples in Canada.
AIDS and behavior 2011;15(1):214-27.
2011: Kathleen N Deering; Thomas Kerr; Mark W Tyndall; Julio S G Montaner; Kate Gibson; Laurel Irons; Kate Shannon
A peer-led mobile outreach program and increased utilization of detoxification and residential drug treatment among female sex workers who use drugs in a Canadian setting.
Drug and alcohol dependence 2011;113(1):46-54.
2010: Mona R Loutfy; Miguel Genebat; David Moore; Janet Raboud; Keith Chan; Tony Antoniou; David Milan; Anya Shen; Marina B Klein; Curtis Cooper; Nima Machouf; Sean B Rourke; Anita Rachlis; Chris Tsoukas; Julio S G Montaner; Sharon L Walmsley; Marek Smieja; Ahmed M Bayoumi; Edward Mills; Hogg Robert
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
Journal of acquired immune deficiency syndromes (1999) 2010;55(4):451-9.
2010: Julio S G Montaner; Evan Wood; Thomas Kerr; Viviane Lima; Rolando Barrios; Kate Shannon; Richard Harrigan; Hogg Robert
Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes.
Journal of acquired immune deficiency syndromes (1999) 2010;55 Suppl 1():S5-9.
2010: Viviane D Lima; David R Bangsberg; P Richard Harrigan; Steven G Deeks; Benita Yip; Hogg Robert; Julio S G Montaner
Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.
Journal of acquired immune deficiency syndromes (1999) 2010;55(4):460-5.
2010: Viviane D Lima; Katherine J Lepik; Wendy Zhang; Katherine A Muldoon; Robert S Hogg; Julio S G Montaner
Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006.
Canadian journal of public health. Revue canadienne de santé publique 2010;101(5):415-9.
2010: Dan Werb; Thomas Kerr; Danya Fast; Jiezhi Qi; Julio S G Montaner; Evan Wood
Drug-related risks among street youth in two neighborhoods in a Canadian setting.
Health & place 2010;16(5):1061-7.
2010: Viviane D Lima; P Richard Harrigan; Martin Sénécal; Benita Yip; Eric Druyts; Hogg Robert; Julio S G Montaner
Epidemiology of antiretroviral multiclass resistance.
American journal of epidemiology 2010;172(4):460-8.
2010: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Hogg Robert; Patricia Daly; Perry Kendall
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
Lancet 2010;376(9740):532-9.
2010: Brandon D L Marshall; Thomas Kerr; Jiezhi Qi; Julio S G Montaner; Evan Wood
Public injecting and HIV risk behaviour among street-involved youth.
Drug and alcohol dependence 2010;110(3):254-8.
2010: Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2010;304(3):321-33.
2010: C Sarai Racey; Wendy Zhang; Eirikka K Brandson; Kimberly A Fernandes; Despina Tzemis; P Richard Harrigan; Julio S G Montaner; Rolando Barrios; Junine Toy; Hogg Robert
HIV antiviral drug resistance: patient comprehension.
AIDS care 2010;22(7):816-26.
2010: Daniel Werb; Edward J Mills; Julio S G Montaner; Evan Wood
Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis.
The Lancet infectious diseases 2010;10(7):464-9.
2010: Mark W Hull; Julio S G Montaner
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Expert opinion on pharmacotherapy 2010;11(8):1433-7.
2010: Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Hogg Robert; Julio S G Montaner; Evan Wood
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.
Addiction (Abingdon, England) 2010;105(5):907-13.
2010: Julio S G Montaner; Viviane D Lima; Brian G Williams
Evaluating outcomes of the President's Emergency Plan for AIDS Relief in Africa.
Annals of internal medicine 2010;152(2):131-2; author reply 132-3.
2010: Viviane D Lima; Hogg Robert; Julio S G Montaner
Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.
PloS one 2010;5(6):e10991.
2010: Viviane D Lima; Eric Druyts; Julio S G Montaner; Hogg Robert
Regional and temporal trends in migration among people living with HIV/AIDS in British Columbia, 1993-2005.
Canadian journal of public health. Revue canadienne de santé publique 2010;101(1):44-9.
2010: Janet M Raboud; Mona R Loutfy; DeSheng Su; Ahmed M Bayoumi; Marina B Klein; Curtis Cooper; Nima Machouf; Sean Rourke; Sharon Walmsley; Anita Rachlis; P Richard Harrigan; Marek Smieja; Christos Tsoukas; Julio S G Montaner; Hogg Robert
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.
BMC infectious diseases 2010;10():40.
2010: Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(1):98-105.
2009: Mark W Hull; Viviane D Lima; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Epidemiology of treatment failure: a focus on recent trends.
Current opinion in HIV and AIDS 2009;4(6):467-73.
2009: Julio S G Montaner; Douglas D Richman; Scott M Hammer
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(8):1283-4.
2009: Viviane Lima; Richard Harrigan; Julio S G Montaner
Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):3-6.
2009: Viviane D Lima; Richard Harrigan; David R Bangsberg; Hogg Robert; Robert Gross; Benita Yip; Julio S G Montaner
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.
Journal of acquired immune deficiency syndromes (1999) 2009;50(5):529-36.
2009: Viviane D Lima; Valeria Fink; Benita Yip; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals.
American journal of public health 2009;99 Suppl 1():S193-6.
2009: Beth S Rachlis; Evan Wood; Ruth Zhang; Julio S G Montaner; Thomas Kerr
High rates of homelessness among a cohort of street-involved youth.
Health & place 2009;15(1):10-7.
2009: Mark W Hull; Marianne Harris; Viviane Lima; Silvia Guillemi; P Richard Harrigan; Julio S G Montaner
Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
Journal of clinical pharmacology 2009;49(2):155-61.
2009: Alexandra Calmy; Nathalie Vallier; Alain Nguyen; Joep Ma Lange; Manuel Battegay; Frank de Wolf; Peter Reiss; Viviane D Lima; Bernard Hirschel; Hogg Robert; Benita Yip; Julio S G Montaner; Ferdinand W Wit
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Antiviral therapy 2009;14(7):931-8.
2009: Kate Shannon; Thomas Kerr; Steffanie A Strathdee; Jean A Shoveller; Julio S G Montaner; Mark W Tyndall
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers.
BMJ (Clinical research ed.) 2009;339():b2939.
2009: Christina Kim; Thomas Kerr; Kathy Li; Ruth Zhang; Mark W Tyndall; Julio S G Montaner; Evan Wood
Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting.
BMC public health 2009;9():270.
2009: Thomas Kerr; Brandon D L Marshall; Cari Miller; Kate Shannon; Ruth Zhang; Julio S G Montaner; Evan Wood
Injection drug use among street-involved youth in a Canadian setting.
BMC public health 2009;9():171.
2009: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.
BMJ (Clinical research ed.) 2009;338():b1649.
2009: Andrew Kiboneka; Ricky Jones Nyatia; Christine Nabiryo; Aranka Anema; Curtis L Cooper; Kimberly Ann Fernandes; Julio S G Montaner; Edward J Mills
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda.
BMJ (Clinical research ed.) 2009;338():b201.
2009: Brandon D L Marshall; Thomas Kerr; Jean A Shoveller; Julio S G Montaner; Evan Wood
Structural factors associated with an increased risk of HIV and sexually transmitted infection transmission among street-involved youth.
BMC public health 2009;9():7.
2009: Elisa Lloyd-Smith; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr
Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectors.
Drug and alcohol dependence 2009;99(1-3):176-82.
2008: David M Moore; Anna Awor; Robert Downing; Jonathan Kaplan; Julio S G Montaner; John Hancock; Willy Were; Jonathan Mermin
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2008;49(5):477-84.
2008: Mark W Hull; Peter Phillips; Julio S G Montaner
Changing global epidemiology of pulmonary manifestations of HIV/AIDS.
Chest 2008;134(6):1287-98.
2008: Lily W Y Tam; Celia K S Chui; Chanson J Brumme; David R Bangsberg; Julio S G Montaner; Hogg Robert; P Richard Harrigan
The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.
Journal of acquired immune deficiency syndromes (1999) 2008;49(3):266-71.
2008: Marianne Harris; Gerene Larsen; Julio S G Montaner
Exacerbation of depression associated with starting raltegravir: a report of four cases.
AIDS (London, England) 2008;22(14):1890-2.
2008: Sarah J Fielden; Melanie L A Rusch; Benita Yip; Evan Wood; Kate Shannon; Adrian R Levy; Julio S G Montaner; Hogg Robert
Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2008;7(5):238-44.
2008: Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2008;300(5):555-70.
2008: Evan Wood; Hogg Robert; Viviane D Lima; Thomas Kerr; Benita Yip; Brandon D L Marshall; Julio S G Montaner
Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
JAMA : the journal of the American Medical Association 2008;300(5):550-4.
2008: Evan Wood; Thomas Kerr; Mark W Tyndall; Julio S G Montaner
A review of barriers and facilitators of HIV treatment among injection drug users.
AIDS (London, England) 2008;22(11):1247-56.
2008: Aranka Anema; Evan Wood; Julio S G Montaner
The use of highly active retroviral therapy to reduce HIV incidence at the population level.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2008;179(1):13-4.
2008: Zia Hoda; Thomas Kerr; Kathy Li; Julio S G Montaner; Evan Wood
Prevalence and correlates of jugular injections among injection drug users.
Drug and alcohol review 2008;27(4):442-6.
2008: Viviane D Lima; Karissa Johnston; Hogg Robert; Adrian R Levy; P Richard Harrigan; Aranka Anema; Julio S G Montaner
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
The Journal of infectious diseases 2008;198(1):59-67.
2008: Viviane D Lima; Vikram S Gill; Benita Yip; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
The Journal of infectious diseases 2008;198(1):51-8.
2008: Marianne Harris; Gerene Larsen; Julio S G Montaner
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
AIDS (London, England) 2008;22(10):1224-6.
2008: Thomas Kerr; William Small; Caitlin Johnston; Kathy Li; Julio S G Montaner; Evan Wood
Characteristics of injection drug users who participate in drug dealing: implications for drug policy.
Journal of psychoactive drugs 2008;40(2):147-52.
2008: Evan Wood; Thomas Kerr; Mark W Tyndall; Julio S G Montaner
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
The International journal on drug policy 2008;19(3):220-5.
2008: R Alan Wood; Evan Wood; Calvin Lai; Mark W Tyndall; Julio S G Montaner; Thomas Kerr
Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility.
The International journal on drug policy 2008;19(3):183-8.
2008: Evan Wood; Jo-Anne Stoltz; Ruth Zhang; Steffanie A Strathdee; Julio S G Montaner; Thomas Kerr
Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth.
Drug and alcohol review 2008;27(3):270-6.
2008: Evan Wood; Julio S G Montaner
Antiretroviral therapy: a key part of the public health response to injection drug use.
Addiction (Abingdon, England) 2008;103(4):660-1.
2008: Ruth Joy; Eric F Druyts; Eirikka K Brandson; Viviane D Lima; Clare A Rustad; Wendy Zhang; Evan Wood; Julio S G Montaner; Hogg Robert
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting.
Journal of acquired immune deficiency syndromes (1999) 2008;47(4):500-5.
2008: Evan Wood; Julio S G Montaner; Kathy Li; Ruth Zhang; Lucy Barney; Steffanie A Strathdee; Mark W Tyndall; Thomas Kerr
Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia.
American journal of public health 2008;98(3):515-9.
2008: Elizabeth Phillips; Anna Hayden; Sonia Gutiérrez; Natalie Jahnke; Benita Yip; Viviane D Lima; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
AIDS (London, England) 2008;22(4):548-9.
2008: Andrew J Low; David Marchant; Chanson J Brumme; Zabrina L Brumme; Winnie Dong; Tobias Sing; Hogg Robert; Julio S G Montaner; Vikram Gill; Peter K Cheung; P Richard Harrigan
CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals.
AIDS research and human retroviruses 2008;24(2):219-28.
2008: Sonia Gutiérrez; Silvia Guillemi; Natalie Jahnke; Valentina Montessori; P Richard Harrigan; Julio S G Montaner
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(3):e28-30.
2008: Elisa Lloyd-Smith; Evan Wood; Ruth Zhang; Mark W Tyndall; Julio S G Montaner; Thomas Kerr
Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study.
BMC public health 2008;8():405.
2007: Ryan Blades; Kathy Li; Thomas Kerr; Mark W Tyndall; Julio S G Montaner; Evan Wood
Contribution of HIV to mortality among injection drug users in the era of HAART.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):655-6.
2007: Mona R Loutfy; M Harris; Janet Raboud; Tony Antoniou; Colin Kovacs; S Shen; S Dufresne; Fiona Smaill; Danielle Rouleau; Anita Rachlis; Kevin Gough; R Lalonde; C Tsoukas; Benoit Trottier; Sharon L Walmsley; Julio S G Montaner
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
HIV medicine 2007;8(7):427-32.
2007: Evan Wood; Thomas Kerr; Mark W Tyndall; Ruth Zhang; Hogg Robert; Steffanie A Strathdee; Julio S G Montaner
Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
Addiction (Abingdon, England) 2007;102(9):1503-5.
2007: Jo-Anne Madeleine Stoltz; Kate Shannon; Thomas Kerr; Ruth Zhang; Julio S G Montaner; Evan Wood
Associations between childhood maltreatment and sex work in a cohort of drug-using youth.
Social science & medicine (1982) 2007;65(6):1214-21.
2007: Mark Hull; Marianne Harris; Julio S G Montaner
Stopping antiretroviral therapy: easier said than done.
AIDS (London, England) 2007;21(13):1817-8.
2007: Jacques Reynes; Keikawus Arastéh; Bonaventura Clotet; Calvin Cohen; David A Cooper; Jean-François Delfraissy; Joseph J Eron; Keith Henry; Christine Katlama; Daniel R Kuritzkes; Jacob P Lalezari; Joep Lange; Adriano Lazzarin; Julio S G Montaner; Mark Nelson; Mary O' Hearn; Hans-Jürgen Stellbrink; Benoit Trottier; Sharon L Walmsley; Neil E Buss; Ralph DeMasi; Jain Chung; Lucille Donatacci; Denise Guimaraes; Lucy Rowell; Adeline Valentine; Martin Wilkinson; Miklos Salgo
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Elizabeth Phillips; Sonia Gutiérrez; Natalie Jahnke; Benita Yip; Viviane D Lima; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
AIDS (London, England) 2007;21(12):1561-8.
2007: Evan Wood; Thomas Kerr; Julio S G Montaner
HIV treatment, injection drug use, and illicit drug policies.
Lancet 2007;370(9581):8-10.
2007: Evan Wood; Julio S G Montaner; Kathy Li; Lucy Barney; Mark W Tyndall; Thomas Kerr
Rate of methadone use among Aboriginal opioid injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2007;177(1):37-40.
2007: Zabrina L Brumme; Chanson J Brumme; David Heckerman; Bette T Korber; Marcus Daniels; Jonathan Carlson; Carl Kadie; Tanmoy Bhattacharya; Celia Chui; James Szinger; Theresa Mo; Hogg Robert; Julio S G Montaner; Nicole Frahm; Christian Brander; Bruce D Walker; P Richard Harrigan
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.
PLoS pathogens 2007;3(7):e94.
2007: L W Y Tam; Hogg Robert; Benita Yip; Julio S G Montaner; P Richard Harrigan; Chanson J Brumme
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
HIV medicine 2007;8(5):267-70.
2007: Thomas Kerr; Mark W Tyndall; Ruth Zhang; Calvin Lai; Julio S G Montaner; Evan Wood
Circumstances of first injection among illicit drug users accessing a medically supervised safer injection facility.
American journal of public health 2007;97(7):1228-30.
2007: Mona R Loutfy; Janet Raboud; Julio S G Montaner; Tony Antoniou; Brian Wynhoven; Fiona Smaill; Danielle Rouleau; J Gill; Walter F Schlech; Zabrina L Brumme; Theresa Mo; Kevin Gough; Anita Rachlis; P R Harrigan; Sharon L Walmsley
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Antiviral research 2007;75(1):58-63.
2007: Mark R Nelson; Christine Katlama; Julio S G Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Evan Wood; Julio S G Montaner
When to initiate HIV antiretroviral therapy: do benefits other than survival deserve greater attention?
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):131-2.
2007: Evan Wood; Mark W Tyndall; Ruth Zhang; Julio S G Montaner; Thomas Kerr
Rate of detoxification service use and its impact among a cohort of supervised injecting facility users.
Addiction (Abingdon, England) 2007;102(6):916-9.
2007: Celia K S Chui; Zabrina L Brumme; Chanson J Brumme; Benita Yip; Elizabeth J Phillips; Julio S G Montaner; P Richard Harrigan
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1503-8.
2007: Zabrina L Brumme; Chanson J Brumme; Celia Chui; Theresa Mo; Brian Wynhoven; Conan K Woods; Bethany M Henrick; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
The Journal of infectious diseases 2007;195(11):1694-704.
2007: Benjamin Maas; Nadia Fairbairn; Thomas Kerr; Kathy Li; Julio S G Montaner; Evan Wood
Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users.
Health & place 2007;13(2):432-9.
2007: Viviane D Lima; Josie Geller; david bangsberg; Thomas L Patterson; Mark Daniel; Thomas Kerr; Julio S G Montaner; Hogg Robert
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.
AIDS (London, England) 2007;21(9):1175-83.
2007: Nadia Fairbairn; Thomas Kerr; Jane A Buxton; Kathy Li; Julio S G Montaner; Evan Wood
Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting.
Drug and alcohol dependence 2007;88(2-3):313-6.
2007: H Ezzat; Douglas Filipenko; Linda M Vickars; P Diane Galbraith; C Li; K Murphy; Julio S G Montaner; Marianne Harris; Hogg Robert; S Vercauteren; Chantal Leger; L Zypchen; Heather A Leitch
Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.
HIV clinical trials 2007;8(3):132-44.
2007: Steven Petrar; Thomas Kerr; Mark W Tyndall; Ruth Zhang; Julio S G Montaner; Evan Wood
Injection drug users' perceptions regarding use of a medically supervised safer injecting facility.
Addictive behaviors 2007;32(5):1088-93.
2007: Julio S G Montaner; Hogg Robert
Hungering for HAART.
Annals of internal medicine 2007;146(8):609-10.
2007: Timothy Christie; Getnet A Asrat; Bashir Jiwani; Thomas Maddix; Julio S G Montaner
Exploring disparities between global HIV/AIDS funding and recent tsunami relief efforts: an ethical analysis.
Developing world bioethics 2007;7(1):1-7.
2007: Viviane D Lima; Hogg Robert; P Richard Harrigan; David Moore; Benita Yip; Evan Wood; Julio S G Montaner
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
AIDS (London, England) 2007;21(6):685-92.
2007: Evan Wood; Hogg Robert; Benita Yip; David Moore; P Richard Harrigan; Julio S G Montaner
Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
HIV medicine 2007;8(2):80-5.
2007: Viviane D Lima; Hogg Robert; Julio S G Montaner
Presenting plasma HIV RNA level and rate of CD4 T-cell decline.
JAMA : the journal of the American Medical Association 2007;297(8):805-6; author reply 806-7.
2007: Evan Wood; Elisa Lloyd-Smith; Kathy Li; Steffanie A Strathdee; Will Small; Mark W Tyndall; Julio S G Montaner; Thomas Kerr
Frequent needle exchange use and HIV incidence in Vancouver, Canada.
The American journal of medicine 2007;120(2):172-9.
2007: Chanson J Brumme; P Richard Harrigan; Emma C Preston; Winnie W Y Dong; Brian Wynhoven; Carol Murphy; Julio S G Montaner
Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
Antiviral therapy 2007;12(7):1139-44.
2007: Ian McKnight; Benjamin Maas; Evan Wood; Mark W Tyndall; Will Small; Calvin Lai; Julio S G Montaner; Thomas Kerr
Factors associated with public injecting among users of Vancouver's supervised injection facility.
The American journal of drug and alcohol abuse 2007;33(2):319-25.
2007: Julio S G Montaner
Modern highly active antiretroviral therapy-a very well tuned compass for a rapidly evolving field.
Enfermedades infecciosas y microbiología clínica 2007;25(1):1-2.
2007: Evan Wood; Hogg Robert; Thomas Kerr; Simon Bonner; Steffanie A Strathdee; Anita Palepu; Julio S G Montaner
Rates of inappropriate antiretroviral prescription among injection drug users.
Harm reduction journal 2007;4():2.
2006: Victoria Alfonso; Nicole Bermbach; Josie Geller; Julio S G Montaner
Individual variability in barriers affecting people's decision to take HAART: a qualitative study identifying barriers to being on HAART.
AIDS patient care and STDs 2006;20(12):848-57.
2006: David M Moore; Jonathan Mermin; Anna Awor; Benita Yip; Hogg Robert; Julio S G Montaner
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.
Journal of acquired immune deficiency syndromes (1999) 2006;43(4):436-9.
2006: Evan Wood; Mark W Tyndall; Julio S G Montaner; Thomas Kerr
Summary of findings from the evaluation of a pilot medically supervised safer injecting facility.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;175(11):1399-404.
2006: Timothy K S Christie; Marianne Harris; Julio S G Montaner
Special Access Denied: A Case Study of Health Canada's Special Access Program.
Healthcare policy = Politiques de santé 2006;2(2):27-34.
2006: Shayesta Dhalla; Keith J Chan; Julio S G Montaner; Hogg Robert
Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy.
Complementary therapies in clinical practice 2006;12(4):242-8.
2006: Cari L Miller; Patricia M Spittal; Evan Wood; Keith Chan; Martin T Schechter; Julio S G Montaner; Hogg Robert
Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations.
AIDS care 2006;18(8):968-76.
2006: Robert Gross; Benita Yip; Vincent Lo Re; Evan Wood; Christopher S Alexander; P Richard Harrigan; david bangsberg; Julio S G Montaner; Hogg Robert
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.
The Journal of infectious diseases 2006;194(8):1108-14.
2006: Paula Braitstein; Kathy Li; T Kerr; Julio S G Montaner; Hogg Robert; Evan Wood
Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
AIDS care 2006;18(7):690-3.
2006: Anita Palepu; Mark W Tyndall; Ruth Joy; Thomas Kerr; Evan Wood; Natasha Press; Hogg Robert; Julio S G Montaner
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Drug and alcohol dependence 2006;84(2):188-94.
2006: Hogg Robert; david bangsberg; Viviane D Lima; Chris Alexander; Simon Bonner; Benita Yip; Evan Wood; Winnie W Y Dong; Julio S G Montaner; P Richard Harrigan
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
PLoS medicine 2006;3(9):e356.
2006: Evan Wood; Thomas Kerr; Hogg Robert; Anita Palepu; Ruth Zhang; Steffanie A Strathdee; Julio S G Montaner
Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
Drug and alcohol review 2006;25(5):451-4.
2006: David M Moore; Hogg Robert; Benita Yip; Kevin J P Craib; Evan Wood; Julio S G Montaner
CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
HIV medicine 2006;7(6):383-8.
2006: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; José M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2006;296(7):827-43.
2006: Julio S G Montaner; Hogg Robert; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.
Lancet 2006;368(9534):531-6.
2006: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; José M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):827-43.
2006: David M Moore; Hogg Robert; Benita Yip; Evan Wood; M Harris; Julio S G Montaner
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
HIV medicine 2006;7(5):311-6.
2006: Celia Chui; Peter K Cheung; Chanson J Brumme; Theresa Mo; Zabrina L Brumme; Julio S G Montaner; andrew badley; P Richard Harrigan
HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.
AIDS research and human retroviruses 2006;22(7):615-8.
2006: Hélène C F Côté; Zabrina L Brumme; Jennifer W Chan; Silvia Guillemi; Julio S G Montaner; P Richard Harrigan
HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?
AIDS (London, England) 2006;20(9):1343-5.
2006: Evan Wood; Mark W Tyndall; Ruth Zhang; Jo-Anne Stoltz; Calvin Lai; Julio S G Montaner; Thomas Kerr
Attendance at supervised injecting facilities and use of detoxification services.
The New England journal of medicine 2006;354(23):2512-4.
2006: Timothy K S Christie; Julio S G Montaner
The perverted irony of Health Canada's Special Access Programme.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;174(12):1746.
2006: Evan Wood; Hogg Robert; Benita Yip; David Moore; P Richard Harrigan; Julio S G Montaner
Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
AIDS (London, England) 2006;20(8):1117-23.
2006: Victoria Alfonso; Josie Geller; Nicole Bermbach; Anne Drummond; Julio S G Montaner
Becoming a "treatment success": what helps and what hinders patients from achieving and sustaining undetectable viral loads.
AIDS patient care and STDs 2006;20(5):326-34.
2006: Evan Wood; Jo-Anne Stoltz; Kathy Li; Julio S G Montaner; Thomas Kerr
Changes in Canadian heroin supply coinciding with the Australian heroin shortage.
Addiction (Abingdon, England) 2006;101(5):689-95.
2006: Evan Wood; Mark W Tyndall; Zhenguo Qui; Ruth Zhang; Julio S G Montaner; Thomas Kerr
Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility.
American journal of public health 2006;96(5):770-3.
2006: Evan Wood; Thomas Kerr; Hogg Robert; Ruth Zhang; Mark W Tyndall; Julio S G Montaner
Validity of self-reported antiretroviral therapy use among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2006;41(4):530-1.
2006: Evan Wood; Thomas Kerr; Anita Palepu; Ruth Zhang; Steffanie A Strathdee; Mark W Tyndall; Julio S G Montaner; Hogg Robert
Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users.
The Journal of infection 2006;52(4):233-6.
2006: Marianne Harris; Gerene Larsen; Monica Valyi; Ekaterina Walker; Julio S G Montaner
Transient neuropathy after needle-free injection outside of recommended sites.
AIDS (London, England) 2006;20(5):784-5.
2006: Marianne Harris; Ruth Joy; Gerene Larsen; Monica Valyi; Ekaterina Walker; Lloyd W Frick; Robin M Palmatier; Stephen A Wring; Julio S G Montaner
Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
AIDS (London, England) 2006;20(5):719-23.
2006: Adrian R Levy; Douglas James; Karissa M Johnston; Hogg Robert; P Richard Harrigan; Brian P Harrigan; Boris Sobolev; Julio S G Montaner
The direct costs of HIV/AIDS care.
The Lancet infectious diseases 2006;6(3):171-7.
2006: Elisa Lloyd-Smith; Elizabeth Brodkin; Evan Wood; Thomas Kerr; Mark W Tyndall; Julio S G Montaner; Hogg Robert
Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
AIDS (London, England) 2006;20(3):445-50.
2006: David M Moore; Hogg Robert; Keith Chan; Mark Tyndall; Benita Yip; Julio S G Montaner
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
AIDS (London, England) 2006;20(3):371-7.
2006: Paula Braitstein; Amy Justice; david bangsberg; Benita Yip; Victoria Alfonso; Martin T Schechter; Hogg Robert; Julio S G Montaner
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort.
AIDS (London, England) 2006;20(3):323-31.
2006: Patricia M Spittal; Hogg Robert; Kathy Li; Kevin J P Craib; Magdalena A Recsky; Charlotte Johnston; Julio S G Montaner; Martin T Schechter; Evan Wood
Drastic elevations in mortality among female injection drug users in a Canadian setting.
AIDS care 2006;18(2):101-8.
2006: Paula Braitstein; Carlos Zala; Benita Yip; Martin W G Brinkhof; David Moore; Hogg Robert; Julio S G Montaner
Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
The Journal of infectious diseases 2006;193(2):259-68.
2006: Mark W Tyndall; Evan Wood; Ruth Zhang; Calvin Lai; Julio S G Montaner; Thomas Kerr
HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment.
Harm reduction journal 2006;3():36.
2006: Julio S G Montaner; Malte Schutz; Robert Schwartz; Dushyantha Jayaweera; Alfred F Burnside; Sharon Walmsley; Michael S Saag
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
MedGenMed : Medscape general medicine 2006;8(2):36.
2006: Laura M Kuyper; Thomas Kerr; Kathy Li; Hogg Robert; Mark W Tyndall; Julio S G Montaner; Evan Wood
Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs.
Substance use & misuse 2006;41(6-7):883-99.
2006: Evan Wood; Jo-Anne Stoltz; Julio S G Montaner; Thomas Kerr
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study.
Harm reduction journal 2006;3():18.
2006: Viviane D Lima; Patricia Kretz; Anita Palepu; Simon Bonner; Thomas Kerr; David Moore; Mark Daniel; Julio S G Montaner; Hogg Robert
Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART.
AIDS research and therapy 2006;3():14.
2006: Evan Wood; Mark W Tyndall; Calvin Lai; Julio S G Montaner; Thomas Kerr
Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime.
Substance abuse treatment, prevention, and policy 2006;1():13.
2006: David M Moore; Hogg Robert; Paula Braitstein; Evan Wood; Benita Yip; Julio S G Montaner
Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Antiviral therapy 2006;11(1):125-9.
2006: Hélène C F Côté; Alex B Magil; Marianne Harris; Brian J Scarth; Izabelle Gadawski; Nancy Wang; Eugenia Yu; Benita Yip; Nadia Zalunardo; Ron Werb; Hogg Robert; P Richard Harrigan; Julio S G Montaner
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Antiviral therapy 2006;11(1):79-86.
2006: Thomas Kerr; Jo-Anne Stoltz; Steffanie A Strathdee; Kathy Li; Hogg Robert; Julio S G Montaner; Evan Wood
The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2006;41(1):119-23.
2005: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary E O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph DeMasi; Jain Chung; Miklos Salgo
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Evan Wood; T Kerr; J Stoltz; Z Qui; R Zhang; Julio S G Montaner; M W Tyndall
Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility.
Public health 2005;119(12):1111-5.
2005: Adrienne R Toulson; Richard Harrigan; Katherine V Heath; Benita Yip; Zabrina L Brumme; Marianne Harris; Hogg Robert; Julio S G Montaner
Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
The Journal of infectious diseases 2005;192(10):1787-93.
2005: Elisa Lloyd-Smith; Thomas Kerr; Hogg Robert; Kathy Li; Julio S G Montaner; Evan Wood
Prevalence and correlates of abscesses among a cohort of injection drug users.
Harm reduction journal 2005;2():24.
2005: David M Moore; Hogg Robert; Benita Yip; Evan Wood; Mark Tyndall; Paula Braitstein; Julio S G Montaner
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
Journal of acquired immune deficiency syndromes (1999) 2005;40(3):288-93.
2005: Courtney L C Collins; Thomas Kerr; Mark W Tyndall; David C Marsh; Patricia S Kretz; Julio S G Montaner; Evan Wood
Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users.
Canadian journal of public health. Revue canadienne de santé publique 2005;96(5):344-7.
2005: Jacqueline M O'Connell; Thomas Kerr; Kathy Li; Mark W Tyndall; Hogg Robert; Julio S G Montaner; Evan Wood
Requiring help injecting independently predicts incident HIV infection among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2005;40(1):83-8.
2005: Marcus Lem; David Moore; Stephen Marion; Simon Bonner; Keith Chan; Jacqueline O'Connell; Julio S G Montaner; Hogg Robert
Back to work: correlates of employment among persons receiving highly active antiretroviral therapy.
AIDS care 2005;17(6):740-6.
2005: Evan Wood; Mark W Tyndall; Kathy Li; Elisa Lloyd-Smith; Will Small; Julio S G Montaner; Thomas Kerr
Do supervised injecting facilities attract higher-risk injection drug users?
American journal of preventive medicine 2005;29(2):126-30.
2005: Zabrina L Brumme; James Goodrich; Howard B Mayer; Chanson J Brumme; Bethany M Henrick; Brian Wynhoven; Jérôme J Asselin; Peter K Cheung; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
The Journal of infectious diseases 2005;192(3):466-74.
2005: Evan Wood; Hogg Robert; Benita Yip; Winnie W Y Dong; Brian Wynhoven; Theresa Mo; Chanson J Brumme; Julio S G Montaner; P Richard Harrigan
Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.
AIDS (London, England) 2005;19(11):1189-95.
2005: Paula Braitstein; Benita Yip; Valentina Montessori; David Moore; Julio S G Montaner; Hogg Robert
Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2005;173(2):160-4.
2005: Laura M Kuyper; Courtney L C Collins; Thomas Kerr; Hogg Robert; Kathy Li; Mark W Tyndall; Julio S G Montaner; Evan Wood
The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2005;16(4):225-9.
2005: Kate Shannon; Thomas Kerr; Calvin Lai; Tomiye Ishida; Evan Wood; Julio S G Montaner; Hogg Robert; Mark W Tyndall
Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2005;4(3):66-72.
2005: Evan Wood; Hogg Robert; P Richard Harrigan; Julio S G Montaner
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.
The Lancet infectious diseases 2005;5(7):407-14.
2005: Courtney L C Collins; Thomas Kerr; Laura M Kuyper; Kathy Li; Mark W Tyndall; David C Marsh; Julio S G Montaner; Evan Wood
Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use.
Journal of urban health : bulletin of the New York Academy of Medicine 2005;82(2):276-84.
2005: Evan Wood; Hogg Robert; Thomas Kerr; Anita Palepu; Ruth Zhang; Julio S G Montaner
Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users.
AIDS (London, England) 2005;19(8):837-9.
2005: Paula Braitstein; Valentina Montessori; Keith Chan; Julio S G Montaner; Martin T Schechter; Michael V O'Shaughnessy; Hogg Robert
Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
AIDS care 2005;17(4):505-15.
2005: P Richard Harrigan; Brian Wynhoven; Zabrina L Brumme; Chanson J Brumme; Beheroze Sattha; Jennifer C Major; Rafael de la Rosa; Julio S G Montaner
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.
The Journal of infectious diseases 2005;191(8):1325-30.
2005: Lena Normén; Keith Chan; Paula Braitstein; Aranka Anema; Greg Bondy; Julio S G Montaner; Hogg Robert
Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada.
The Journal of nutrition 2005;135(4):820-5.
2005: Evan Wood; Kathy Li; Will Small; Julio S G Montaner; Martin T Schechter; Thomas Kerr
Recent incarceration independently associated with syringe sharing by injection drug users.
Public health reports (Washington, D.C. : 1974) 2005;120(2):150-6.
2005: Carlos Zala; Christopher S Alexander; Claudia Ochoa; Silvia Guillemi; Lillian S L Ting; Simon Bonner; Pedro Cahn; P Richard Harrigan; Julio S G Montaner
Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):363-4.
2005: Frank van Leth; Casper B Huisamen; Roberto Badaro; Bernard Vandercam; Joss de Wet; Julio S G Montaner; David B Hall; Ferdinand W N M Wit; Joep M A Lange
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):296-300.
2005: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Julio S G Montaner
Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):289-95.
2005: P Richard Harrigan; Hogg Robert; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Justin Woodward; Chanson J Brumme; Zabrina L Brumme; Theresa Mo; Christopher S Alexander; Julio S G Montaner
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.
The Journal of infectious diseases 2005;191(3):339-47.
2005: Evan Wood; Kathy Li; Cari L Miller; Hogg Robert; Julio S G Montaner; Martin T Schechter; Thomas Kerr
Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users.
International journal of epidemiology 2005;34(1):152-8.
2005: Zabrina L Brumme; Bethany M Henrick; Chanson J Brumme; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Antiviral therapy 2005;10(7):849-53.
2005: Evan Wood; Kathy Li; Anita Palepu; David C Marsh; Martin T Schechter; Hogg Robert; Julio S G Montaner; Thomas Kerr
Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users.
Substance use & misuse 2005;40(8):1153-67.
2005: Mark A Wainberg; James P C Sawyer; Julio S G Montaner; Robert L Murphy; Daniel R Kuritzkes; Francois Raffi
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Antiviral therapy 2005;10(1):13-28.
2005: Adrian R Levy; Lawrence McCandless; P Richard Harrigan; Hogg Robert; Gregory P Bondy; Uchenna H Iloeje; Jayanti Mukherjee; Julio S G Montaner
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
Lipids in health and disease 2005;4():4.
2004: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Julio S G Montaner
Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence.
AIDS (London, England) 2004;18(18):2432-4.
2004: Laura M Kuyper; Evan Wood; Julio S G Montaner; Benita Yip; Jacqueline M O'Connell; Hogg Robert
Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
Journal of acquired immune deficiency syndromes (1999) 2004;37(4):1470-6.
2004: Laura M Kuyper; Hogg Robert; Julio S G Montaner; Martin T Schechter; Evan Wood
The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions.
Journal of urban health : bulletin of the New York Academy of Medicine 2004;81(4):655-60.
2004: Thomas Kerr; Alex Wodak; Richard Elliott; Julio S G Montaner; Evan Wood
Opioid substitution and HIV/AIDS treatment and prevention.
Lancet 2004;364(9449):1918-9.
2004: Paula Braitstein; Anita Palepu; Douglas Dieterich; Yves Benhamou; Julio S G Montaner
Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.
AIDS (London, England) 2004;18(17):2221-34.
2004: Jorge F Quarleri; Andrea Elena Rubio; Mauricio Carobene; Gabriela Turk; Moira Vignoles; Richard P Harrigan; Julio S G Montaner; Horacio Salomón; Manuel Gómez-Carrillo
HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns: descriptive analysis from 284 patients under treatment failure.
AIDS research and human retroviruses 2004;20(10):1100-7.
2004: Anita Palepu; Mark W Tyndall; Keith Chan; Evan Wood; Julio S G Montaner; Hogg Robert
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Antiviral therapy 2004;9(5):713-9.
2004: Christopher S Alexander; Julio S G Montaner; Jérôme J Asselin; Lillian S L Ting; Kelly McNabb; Marianne Harris; Silvia Guillemi; P Richard Harrigan
Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
Therapeutic drug monitoring 2004;26(5):516-23.
2004: Evan Wood; Thomas Kerr; Will Small; Kathy Li; David C Marsh; Julio S G Montaner; Mark W Tyndall
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;171(7):731-4.
2004: Evan Wood; Hogg Robert; Simon Bonner; Thomas Kerr; Kathy Li; Anita Palepu; Silvia Guillemi; Martin T Schechter; Julio S G Montaner
Staging for antiretroviral therapy among HIV-infected drug users.
JAMA : the journal of the American Medical Association 2004;292(10):1175-7.
2004: Marianne Harris; Julio S G Montaner
Management of HIV-infected patients with multidrug-resistant virus.
Current HIV/AIDS reports 2004;1(3):116-21.
2004: Mona R Loutfy; Janet Raboud; Sharon L Walmsley; Refik Saskin; Julio S G Montaner; Hogg Robert; Courtney A Thompson; P Richard Harrigan
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
Antiviral therapy 2004;9(4):595-602.
2004: Magdalena A Recsky; Zabrina L Brumme; Keith J Chan; Brian Wynhoven; Benita Yip; Winnie W Y Dong; Katherine V Heath; Julio S G Montaner; Adrian R Levy; Hogg Robert; P Richard Harrigan
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
The Journal of infectious diseases 2004;190(2):285-92.
2004: Martin S King; Barry Bernstein; Sharon L Walmsley; Renslow Sherer; Judith Feinberg; Ian Sanne; Paul Cernohous; Julio S G Montaner; Scott C Brun; Eugene Sun
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
The Journal of infectious diseases 2004;190(2):280-4.
2004: Patrick G Yeni; Scott M Hammer; Martin S Hirsch; Michael S Saag; Mauro Schechter; Charles C J Carpenter; Margaret A Fischl; José M Gatell; Brian G Gazzard; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Paul A Volberding
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2004;292(2):251-65.
2004: Evan Wood; Patricia M Spittal; Kathy Li; Thomas Kerr; Cari L Miller; Hogg Robert; Julio S G Montaner; Martin T Schechter
Inability to access addiction treatment and risk of HIV infection among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):750-4.
2004: Cari L Miller; Evan Wood; Patricia M Spittal; Kathy Li; James C Frankish; Paula Braitstein; Julio S G Montaner; Martin T Schechter
The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):743-9.
2004: Evan Wood; Patricia M Spittal; Will Small; Thomas Kerr; Kathy Li; Hogg Robert; Mark W Tyndall; Julio S G Montaner; Martin T Schechter
Displacement of Canada's largest public illicit drug market in response to a police crackdown.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(10):1551-6.
2004: Natasha Press; Julio S G Montaner; Gregory P Bondy
Resolution of diabetes after initiation of antiretroviral therapy in two human immunodeficiency virus-infected patients.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2004;10(3):199-202.
2004: E Castillo; Anita Palepu; A Beardsell; L Akagi; Benita Yip; Julio S G Montaner; Hogg Robert
Outpatient pharmacy care and HIV viral load response among patients on HAART.
AIDS care 2004;16(4):446-57.
2004: Evan Wood; Thomas Kerr; Julio S G Montaner; Steffanie A Strathdee; Alex Wodak; Catherine A Hankins; Martin T Schechter; Mark W Tyndall
Rationale for evaluating North America's first medically supervised safer-injecting facility.
The Lancet infectious diseases 2004;4(5):301-6.
2004: Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Hogg Robert
Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Antiviral therapy 2004;9(2):229-35.
2004: Zabrina L Brumme; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Noah G Hoffman; Ronald Swanstrom; Mark A Jensen; James I Mullins; Hogg Robert; Julio S G Montaner; P Richard Harrigan
Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.
AIDS (London, England) 2004;18(4):F1-9.
2004: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Julio S G Montaner
Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 2004;56(2):232-6.
2004: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
The impact of adherence on CD4 cell count responses among HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2004;35(3):261-8.
2004: Julio S G Montaner; Hélène C F Côté; Marianne Harris; Hogg Robert; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy
Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38 Suppl 2():S73-9.
2004: Rafael de la Rosa; Marianne Harris; Linda Uyeda; Karin Goodison; Paul Keown; Julio S G Montaner
Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
AIDS (London, England) 2004;18(3):578-9.
2004: Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Adverse effects of antiretroviral therapy for HIV infection.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(2):229-38.
2003: Evan Wood; Hogg Robert; Katherine V Heath; Rafael de la Rosa; Nelson Lee; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
AIDS (London, England) 2003;17(18):2629-34.
2003: Jacqueline M O'Connell; Paula Braitstein; Hogg Robert; Benita Yip; Kevin J P Craib; Michael V O'Shaughnessy; Julio S G Montaner; David R Burdge
Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.
Antiviral therapy 2003;8(6):569-76.
2003: Anita Palepu; Mark W Tyndall; Kathy Li; Benita Yip; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner; Hogg Robert
Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
Journal of urban health : bulletin of the New York Academy of Medicine 2003;80(4):667-75.
2003: Evan Wood; Julio S G Montaner; david bangsberg; Mark W Tyndall; Steffanie A Strathdee; Michael V O'Shaughnessy; Hogg Robert
Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.
AIDS (London, England) 2003;17(17):2419-27.
2003: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Annals of internal medicine 2003;139(10):810-6.
2003: Evan Wood; Hogg Robert; Benita Yip; Romina Quercia; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.
The Journal of infectious diseases 2003;188(10):1421-5.
2003: Evan Wood; Hogg Robert; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
Journal of acquired immune deficiency syndromes (1999) 2003;34(3):347-8.
2003: Evan Wood; Julio S G Montaner; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Hogg Robert
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.
The Journal of infectious diseases 2003;188(8):1164-70.
2003: Juan Delgado; Katherine V Heath; Benita Yip; Stephen Marion; Victoria Alfonso; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.
Antiviral therapy 2003;8(5):471-8.
2003: P Richard Harrigan; Kurt Hertogs; Werner Verbiest; Brendan Larder; Benita Yip; Zabrina L Brumme; Christopher Alexander; Jessica Tilley; Michael V O'Shaughnessy; Julio S G Montaner
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Antiviral therapy 2003;8(5):395-402.
2003: Richard Bedell; Katherine V Heath; Hogg Robert; Evan Wood; Natasha Press; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner
Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Antiviral therapy 2003;8(5):379-84.
2003: Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Hogg Robert
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2003;169(7):656-61.
2003: Paula Braitstein; Benita Yip; Katherine V Heath; Adrian R Levy; Julio S G Montaner; Karin H Humphries; F Michael Kiely; Michael V O'Shaughnessy; Hogg Robert
Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000.
AIDS (London, England) 2003;17(14):2071-5.
2003: Julio S G Montaner; Hélène C F Côté; Marianne Harris; Hogg Robert; Benita Yip; Jennifer W Chan; P Richard Harrigan; Michael V O'Shaughnessy
Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S85-90.
2003: Christopher S Alexander; Jérôme J Asselin; Lillian S L Ting; Julio S G Montaner; Hogg Robert; Benita Yip; Michael V O'Shaughnessy; P Richard Harrigan
Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.
The Journal of infectious diseases 2003;188(4):541-8.
2003: Nelson Lee; Hogg Robert; Benita Yip; P Richard Harrigan; Marianne Harris; Michael V O'Shaughnessy; Julio S G Montaner
Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.
The Journal of infectious diseases 2003;188(1):137-41.
2003: Hélène C F Côté; Benita Yip; Jérôme J Asselin; Jennifer W Chan; Hogg Robert; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.
The Journal of infectious diseases 2003;187(12):1972-6.
2003: Julio S G Montaner
Challenges of the unmet needs in the treatment-experienced patient.
The AIDS reader 2003;13(6 Suppl):S5-9.
2003: Jacob P Lalezari; Keith Henry; Mary E O'Hearn; Julio S G Montaner; Peter J Piliero; Benoit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine 2003;348(22):2175-85.
2003: Kenny C Chan; Richard A Galli; Julio S G Montaner; P Richard Harrigan
Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection.
AIDS (London, England) 2003;17(8):1256-8.
2003: Charles Hicks; Julio S G Montaner; Ronald Baker; Michael Youle
Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections.
HIV clinical trials 2003;4(3):202-26.
2003: Valentina Montessori; Marianne Harris; Julio S G Montaner
Hepatotoxicity of nucleoside reverse transcriptase inhibitors.
Seminars in liver disease 2003;23(2):167-72.
2003: Julio S G Montaner; Pedro Cahn; Carlos Zala; Lidia I Casssetti; Marcelo H Losso; David B Hall; Jan Wruck; Marita McDonough; Maria Gigliotti; Patrick A Robinson
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Journal of acquired immune deficiency syndromes (1999) 2003;33(1):41-6.
2003: Emma L Hammond; David C Sayer; David Nolan; Ulrich A Walker; Anthony de Ronde; Julio S G Montaner; Helene C F Cote; Michelle E Gahan; Catherine L Cherry; Steven L Wesselingh; Peter Reiss; Simon Mallal
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;27(1):97-110.
2003: Anita Palepu; Mark Tyndall; Benita Yip; Michael V O'Shaughnessy; Hogg Robert; Julio S G Montaner
Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
Journal of acquired immune deficiency syndromes (1999) 2003;32(5):522-6.
2003: Zabrina L Brumme; Keith J Chan; Winnie W Y Dong; Brian Wynhoven; Theresa Mo; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; P Richard Harrigan
Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.
Antiviral therapy 2003;8(2):91-6.
2003: Evan Wood; Hogg Robert; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
AIDS (London, England) 2003;17(5):711-20.
2003: Zabrina L Brumme; Winnie W Y Dong; Keith J Chan; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; P Richard Harrigan
Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.
AIDS (London, England) 2003;17(2):201-8.
2003: Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Aslam H Anis; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2003;168(2):165-9.
2003: Gustavo H Kijak; Andrea Elena Rubio; Sandra Pampuro; Carlos Zala; Pedro Cahn; R Galli; Julio S G Montaner; Horacio Salomón
Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.
HIV medicine 2003;4(1):72-8.
2003: Katherine V Heath; Julio S G Montaner; Gregory P Bondy; Joel Singer; Michael V O'Shaughnessy; Hogg Robert
Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.
Current drug targets 2003;4(1):13-22.
2002: Natasha Press; Mark W Tyndall; Evan Wood; Hogg Robert; Julio S G Montaner
Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.
Journal of acquired immune deficiency syndromes (1999) 2002;31 Suppl 3():S112-7.
2002: Carlos Zala; Marianne Harris; Claudia Ochoa; Mariel Tocci; Romina Quercia; Graciela Mittelman; Héctor Perez; Pedro Cahn; Julio S G Montaner
Venous and arterial blood lactate in HIV-infected patients.
Antiviral therapy 2002;7(4):309-10.
2002: Marianne Harris; Keith J Chan; Alicja M Tesiorowski; Hogg Robert; Frances M Rosenberg; Clifford Chan Yan; Julio S G Montaner
Random venous lactate levels among HIV-positive patients on antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(4):448-50.
2002: Evan Wood; Julio S G Montaner; Keith Chan; Mark W Tyndall; Martin T Schechter; david bangsberg; Michael V O'Shaughnessy; Hogg Robert
Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.
AIDS (London, England) 2002;16(15):2065-72.
2002: Katherine V Heath; Keith J Chan; Joel Singer; Michael V O'Shaughnessy; Julio S G Montaner; Hogg Robert
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.
International journal of epidemiology 2002;31(5):1016-20.
2002: Alicja M Tesiorowski; Marianne Harris; Keith J Chan; Christopher Thompson; Julio S G Montaner
Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(2):250-1.
2002: Katherine V Heath; Joel Singer; Michael V O'Shaughnessy; Julio S G Montaner; Hogg Robert
Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(2):211-7.
2002: Zabrina L Brumme; Keith J Chan; Winnie W Y Dong; Theresa Mo; Brian Wynhoven; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; P Richard Harrigan
No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.
AIDS (London, England) 2002;16(14):1929-33.
2002: Cari L Miller; Caitlin Johnston; Patricia M Spittal; Kathy Li; Nancy Laliberté; Julio S G Montaner; Martin T Schechter
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Hepatology (Baltimore, Md.) 2002;36(3):737-42.
2002: Kenny C W Chan; Benita Yip; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy
Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.
AIDS (London, England) 2002;16(12):1693-5.
2002: Janet Raboud; Sandra Rae; Ryan Woods; Marianne Harris; Julio S G Montaner
Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.
AIDS (London, England) 2002;16(12):1627-32.
2002: Katherine V Heath; Hogg Robert; Joel Singer; Keith J Chan; Michael V O'Shaughnessy; Julio S G Montaner
Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
Journal of acquired immune deficiency syndromes (1999) 2002;30(4):440-7.
2002: Michael L Rekart; Mel Krajden; Darrel Cook; Gail McNabb; Tony Rees; Judith Isaac-Renton; Marianne Harris; Julio S G Montaner
Problems with the fast-check HIV rapid test kits.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;167(2):119.
2002: Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; José M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Paul A Volberding
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2002;288(2):222-35.
2002: Evan Wood; Hogg Robert; Benita Yip; Mark W Tyndall; Christopher H Sherlock; Richard P Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;30(2):159-66.
2002: Marianne Harris; David Back; Stephen Kewn; Salima Jutha; Raymond B Marina; Julio S G Montaner
Intracellular carbovir triphosphate levels in patients taking abacavir once a day.
AIDS (London, England) 2002;16(8):1196-7.
2002: Paula Braitstein; Keith Chan; Ann Beardsell; Alistair McLeod; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Prescribing practices in a population-based HIV postexposure prophylaxis program.
AIDS (London, England) 2002;16(7):1067-70.
2002: Hogg Robert; Katherine V Heath; david bangsberg; Benita Yip; Natasha Press; Michael V O'Shaughnessy; Julio S G Montaner
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.
AIDS (London, England) 2002;16(7):1051-8.
2002: Paula Braitstein; Keith Chan; Ann Beardsell; Alistair McLeod; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):547-8.
2002: Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.
AIDS (London, England) 2002;16(6):941-3.
2002: Janet Raboud; M Harris; Sandra Rae; Julio S G Montaner
Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy.
HIV medicine 2002;3(2):118-24.
2002: Carlos Zala; Horacio Salomon; Claudia Ochoa; Gustavo H Kijak; Andrea Federico; Héctor Perez; Julio S G Montaner; Pedro Cahn
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2002;29(4):368-73.
2002: Marianne Harris; Chris Alexander; Michael O'Shaughnessy; Julio S G Montaner
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
AIDS (London, England) 2002;16(5):798-9.
2002: Hogg Robert; Diane V Havlir; Veronica Miller; Julio S G Montaner
To stop or not to stop: that is the question, but what is the answer?
AIDS (London, England) 2002;16(5):787-9.
2002: Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian S L Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.
The New England journal of medicine 2002;346(11):811-20.
2002: Christopher S Alexander; Valentina Montessori; Brian Wynhoven; Winnie Dong; Keith Chan; Michael V O'Shaughnessy; Theresa Mo; Magda Piaseczny; Julio S G Montaner; P Richard Harrigan
Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.
Antiviral therapy 2002;7(1):31-5.
2002: Michael Grant; Ingrid Pardoe; Mark Whaley; Julio S G Montaner; P Richard Harrigan
The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.
AIDS (London, England) 2002;16(2):287-90.
2002: Natasha Press; Gil Kimel; Marianne Harris; Benita Yip; Kevin J P Craib; Julio S G Montaner
Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.
HIV clinical trials 2002;3(1):17-20.
2001: Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Industry-sponsored clinical research: a double-edged sword.
Lancet 2001;358(9296):1893-5.
2001: Hogg Robert; Benita Yip; Keith J Chan; Evan Wood; Kevin J P Craib; Michael V O'Shaughnessy; Julio S G Montaner
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
JAMA : the journal of the American Medical Association 2001;286(20):2568-77.
2001: Paula Braitstein; Keith Chan; Ann Beardsell; Alistair McLeod; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme.
AIDS (London, England) 2001;15(17):2345-7.
2001: Zabrina L Brumme; Keith J Chan; W Dong; Hogg Robert; Michael V O'Shaughnessy; Julio S G Montaner; P Richard Harrigan
CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.
AIDS (London, England) 2001;15(17):2259-66.
2001: P Richard Harrigan; Julio S G Montaner; Scott Wegner; Werner Verbiest; Veronica Miller; R Wood; Brendan Larder
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
AIDS (London, England) 2001;15(13):1671-7.
2001: Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Thomas Kerr; Hogg Robert; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2001;165(4):405-10.
2001: Brian Conway; Mark A Wainberg; D Hall; Marianne Harris; P Reiss; D Cooper; STEFANO VELLA; R Curry; P Robinson; J M Lange; Julio S G Montaner
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
AIDS (London, England) 2001;15(10):1269-74.
2001: Christopher S Alexander; Winnie Dong; Keith Chan; Natalie Jahnke; Michael V O'Shaughnessy; Theresa Mo; M A Piaseczny; Julio S G Montaner; P Richard Harrigan
HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.
AIDS (London, England) 2001;15(5):601-7.
2001: Paula Braitstein; T Kendall; Keith Chan; Evan Wood; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV-positive individuals using medical marijuana and antiretroviral agents.
AIDS (London, England) 2001;15(4):532-3.
2001: Anita Palepu; Benita Yip; C Miller; Steffanie A Strathdee; Michael V O'Shaughnessy; Julio S G Montaner; Hogg Robert
Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.
AIDS (London, England) 2001;15(3):423-4.
2001: Julio S G Montaner; P Richard Harrigan; Natalie Jahnke; Janet Raboud; E Castillo; Hogg Robert; Benita Yip; Marianne Harris; Valentina Montessori; Michael V O'Shaughnessy
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.
AIDS (London, England) 2001;15(1):61-9.
2000: Aslam H Anis; Daphne P Guh; Hogg Robert; X H Wang; Benita Yip; Kevin J P Craib; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner
The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.
PharmacoEconomics 2000;18(4):393-404.
2000: Carlos Zala; C Ochoa; Alejandro Krolewiecki; P Patterson; Pedro Cahn; R I Crawford; Julio S G Montaner
Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals.
AIDS (London, England) 2000;14(14):2217-8.
2000: Evan Wood; Benita Yip; Hogg Robert; Christopher H Sherlock; Natalie Jahnke; R P Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy.
AIDS (London, England) 2000;14(13):1955-60.
2000: Evan Wood; Keith Chan; Julio S G Montaner; Martin T Schechter; Mark Tyndall; Michael V O'Shaughnessy; Hogg Robert
The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?
Social science & medicine (1982) 2000;51(5):741-8.
2000: Valentina Montessori; Danielle Rouleau; Janet Raboud; Sandra Rae; I Woo; Julio S G Montaner; Brian Conway
Clinical characteristics of primary HIV infection in injection drug users.
AIDS (London, England) 2000;14(12):1868-70.
2000: Janet Raboud; Sandra Rae; Julio S G Montaner
Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups.
Journal of acquired immune deficiency syndromes (1999) 2000;24(5):433-9.
2000: Evan Wood; Paula Braitstein; Julio S G Montaner; Martin T Schechter; M W Tyndall; Michael V O'Shaughnessy; Hogg Robert
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa.
Lancet 2000;355(9221):2095-100.
2000: Evan Wood; Martin T Schechter; Mark W Tyndall; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Antiretroviral medication use among injection drug users: two potential futures.
AIDS (London, England) 2000;14(9):1229-35.
2000: Carlos Zala; Danielle Rouleau; Julio S G Montaner
Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30 Suppl 2():S143-50.
2000: S Low-Beer; Benita Yip; Michael V O'Shaughnessy; Hogg Robert; Julio S G Montaner
Adherence to triple therapy and viral load response.
Journal of acquired immune deficiency syndromes (1999) 2000;23(4):360-1.
2000: S Low-Beer; Keith Chan; Benita Yip; Evan Wood; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Depressive symptoms decline among persons on HIV protease inhibitors.
Journal of acquired immune deficiency syndromes (1999) 2000;23(4):295-301.
2000: Amy E Weber; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner; Hogg Robert
Determinants of hospital admission among HIV-positive people in British Columbia.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2000;162(6):783-6.
2000: Evan Wood; Benita Yip; N Gataric; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter; Hogg Robert
Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program.
Health & place 2000;6(1):33-40.
2000: S Low-Beer; Amy E Weber; Kim Bartholomew; Monica A Landolt; Doug Oram; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk.
AIDS (London, England) 2000;14(3):325-6.
2000: Julio S G Montaner; Theresa Mo; Janet Raboud; Sandra Rae; Christopher S Alexander; Carlos Zala; Danielle Rouleau; P Richard Harrigan
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
The Journal of infectious diseases 2000;181(2):729-32.
2000: Charles C J Carpenter; D A Cooper; Margaret A Fischl; José M Gatell; Brian G Gazzard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(3):381-90.
2000: S Low-Beer; Keith Chan; Evan Wood; Benita Yip; Julio S G Montaner; Michael V O'Shaughnessy; Hogg Robert
Health related quality of life among persons with HIV after the use of protease inhibitors.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000;9(8):941-9.
2000: Peter G A Cornelisse; Valentina Montessori; Benita Yip; Kevin J P Craib; Michael V O'Shaughnessy; Julio S G Montaner; Hogg Robert
The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy.
International journal of STD & AIDS 2000;11(1):52-6.
1999: Janet Raboud; Sandra Rae; STEFANO VELLA; P Richard Harrigan; Raffaella Bucciardini; Vincenzo Fragola; D Ricciardulli; Julio S G Montaner
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Journal of acquired immune deficiency syndromes (1999) 1999;22(3):260-6.
1999: P Richard Harrigan; Kurt Hertogs; Werner Verbiest; Rudi Pauwels; Brendan Larder; S Kemp; Stuart Bloor; Benita Yip; Hogg Robert; C Alexander; Julio S G Montaner
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
AIDS (London, England) 1999;13(14):1863-71.
1999: Janet Raboud; Sandra Rae; Hogg Robert; Benita Yip; Christopher H Sherlock; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.
The Journal of infectious diseases 1999;180(4):1347-50.
1999: Natalie Jahnke; Benita Yip; Hogg Robert; M O'Shaughnessy; Julio S G Montaner
Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study.
Journal of acquired immune deficiency syndromes (1999) 1999;21(4):347-8.
1999: Christopher S Alexander; Winnie Dong; Martin T Schechter; Michael V O'Shaughnessy; Steffanie A Strathdee; Theresa Mo; Julio S G Montaner; P Richard Harrigan
Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.
AIDS (London, England) 1999;13(8):981-5.
1999: P Richard Harrigan; M Whaley; Julio S G Montaner
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.
AIDS (London, England) 1999;13(8):F59-62.
1999: Julio S G Montaner
Induction/maintenance treatment regimens for HIV.
JAMA : the journal of the American Medical Association 1999;281(18):1680-2.
1999: Dave M Forrest; Carlos Zala; Ognjenka Djurdjev; Joel Singer; Kevin J P Craib; L Lawson; James A Russell; Julio S G Montaner
Determinants of short- and long-term outcome in patients with respiratory failure caused by AIDS-related Pneumocystis carinii pneumonia.
Archives of internal medicine 1999;159(7):741-7.
1999: Brian Conway; Valentina Montessori; Danielle Rouleau; Julio S G Montaner; Michael V O'Shaughnessy; S Fransen; A Shillington; O Weislow; DL Mayers
Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(4):910-1.
1999: Julio S G Montaner; Valentina Montessori; R Harrigan; Michael O'Shaughnessy; Hogg Robert
Antiretroviral therapy: 'the state of the art'.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1999;53(2):63-72.
1999: Nadine Pakker; E D Kroon; Marijke Th L Roos; Sigrid A Otto; D Hall; Ferdinand W N M Wit; Dörte Hamann; Marchina E Van Der Ende; Frans A Claessen; Robbert H Kauffmann; Peter P Koopmans; Frank P Kroon; C H ten Napel; Herman Sprenger; Hugo M Weigel; Julio S G Montaner; Joep M A Lange; Peter Reiss; P T A Schellekens; Frank Miedema
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
AIDS (London, England) 1999;13(2):203-12.
1999: Natalie Jahnke; E Seminari; Hogg Robert; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner
Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
Antiviral therapy 1999;4(3):151-6.
1998: Julio S G Montaner; Hogg Robert; Janet Raboud; R Harrigan; Michael O'Shaughnessy
Antiretroviral treatment in 1998.
Lancet 1998;352(9144):1919-22.
1998: Dave M Forrest; E Seminari; Hogg Robert; Benita Yip; Janet Raboud; L Lawson; P Phillips; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(6):1379-85.
1998: Hogg Robert; Amy E Weber; Kevin J P Craib; A H Anis; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner
One world, one hope: the cost of providing antiretroviral therapy to all nations.
AIDS (London, England) 1998;12(16):2203-9.
1998: Sandra Rae; Janet Raboud; Brian Conway; P Reiss; STEFANO VELLA; D Cooper; J Lange; Marianne Harris; Mark A Wainberg; P Robinson; M Myers; D Hall; Julio S G Montaner
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
AIDS (London, England) 1998;12(16):2185-92.
1998: Janet Raboud; E Seminari; Sandra Rae; P Richard Harrigan; Hogg Robert; Brian Conway; Christopher H Sherlock; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.
Journal of clinical microbiology 1998;36(11):3369-71.
1998: Julio S G Montaner; Janet Raboud; Sandra Rae; STEFANO VELLA
British HIV Association guidelines.
Lancet 1998;352(9135):1226-7.
1998: Janet Raboud; Julio S G Montaner; Brian Conway; Sandra Rae; P Reiss; STEFANO VELLA; D Cooper; J Lange; Marianne Harris; Mark A Wainberg; P Robinson; M Myers; D Hall
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
AIDS (London, England) 1998;12(13):1619-24.
1998: PJ Veugelers; Peter G A Cornelisse; Kevin J P Craib; Stephen A Marion; Hogg Robert; Steffanie A Strathdee; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Models of survival in HIV infection and their use in the quantification of treatment benefits.
American journal of epidemiology 1998;148(5):487-96.
1998: Steffanie A Strathdee; Hogg Robert; Steve L Martindale; Peter G A Cornelisse; Kevin J P Craib; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(1):61-6.
1998: SA Rhone; Hogg Robert; Benita Yip; Christopher H Sherlock; Brian Conway; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?
The Journal of infectious diseases 1998;178(3):662-8.
1998: Steffanie A Strathdee; Anita Palepu; Peter G A Cornelisse; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner; Martin T Schechter; Hogg Robert
Barriers to use of free antiretroviral therapy in injection drug users.
JAMA : the journal of the American Medical Association 1998;280(6):547-9.
1998: Katherine V Heath; O Frank; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter; Hogg Robert
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) mortality in industrialized nations, 1987-1991.
International journal of epidemiology 1998;27(4):685-90.
1998: Dave M Forrest; Ognjenka Djurdjev; Carlos Zala; Joel Singer; L Lawson; James A Russell; Julio S G Montaner
Validation of the modified multisystem organ failure score as a predictor of mortality in patients with AIDS-related Pneumocystis carinii pneumonia and respiratory failure.
Chest 1998;114(1):199-206.
1998: Charles C J Carpenter; Margaret A Fischl; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 1998;280(1):78-86.
1998: Aslam H Anis; Hogg Robert; X H Wang; Benita Yip; Anita Palepu; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
PharmacoEconomics 1998;13(6):697-705.
1998: Marianne Harris; C Durakovic; Sandra Rae; Janet Raboud; S Fransen; A Shillington; Brian Conway; Julio S G Montaner
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
The Journal of infectious diseases 1998;177(6):1514-20.
1998: SA Rhone; Hogg Robert; Benita Yip; Christopher H Sherlock; Brian Conway; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
AIDS (London, England) 1998;12(6):619-24.
1998: Christos M Tsoukas; J Raboud; Nicole F Bernard; Julio S G Montaner; M J Gill; A Rachlis; Ignatius W Fong; Walter F Schlech; O Djurdjev; J Freedman; R Thomas; R Lafrenière; Mark A Wainberg; S Cassol; Michael O'Shaughnessy; J Todd; F Volvovitz; G E Smith
Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
AIDS research and human retroviruses 1998;14(6):483-90.
1998: Julio S G Montaner; Ralph DeMasi; AM Hill
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
AIDS (London, England) 1998;12(5):F23-8.
1998: Hogg Robert; SA Rhone; Benita Yip; Christopher H Sherlock; Brian Conway; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
AIDS (London, England) 1998;12(3):279-84.
1998: Hogg Robert; Katherine V Heath; Benita Yip; Kevin J P Craib; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
JAMA : the journal of the American Medical Association 1998;279(6):450-4.
1998: Hogg Robert; Janet Raboud; M Bigham; Julio S G Montaner; Michael O'Shaughnessy; Martin T Schechter
Relation between hospital HIV/AIDS caseload and mortality among persons with HIV/AIDS in Canada.
Clinical and investigative medicine. Médecine clinique et experimentale 1998;21(1):27-32.
1998: Julio S G Montaner; A Shillington; L J Gonzalez Montaner
HIV/AIDS treatment: lessons from the tuberculosis experience.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 1998;1(3):157-60.
1998: Horacio Salomon; Julio S G Montaner; A Belmonte; Mark A Wainberg
Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase.
Antiviral therapy 1998;3(3):177-82.
1997: Janet Raboud; Julio S G Montaner; Sandra Rae; J Kahn; S M Hammer; D A Katzenstein; Andrew T Pavia; R Dolin; M D Hughes; Anne Cross; M Beltangady; J Gatell; LM Dunkle; L Smaldone
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Antiviral therapy 1997;2(4):237-47.
1997: Katherine V Heath; Hogg Robert; Joel Singer; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
Adherence to clinical guidelines for the therapeutic management of HIV disease.
Clinical and investigative medicine. Médecine clinique et experimentale 1997;20(6):381-7.
1997: Katherine V Heath; Hogg Robert; Janet Raboud; Julio S G Montaner; Michael O'Shaughnessy; Martin T Schechter
Gender differentials in patterns of hospitalization for persons with HIV/AIDS.
AIDS (London, England) 1997;11(14):1788-9.
1997: Marianne Harris; P Patenaude; Peter L Cooperberg; Douglas Filipenko; A Thorne; Janet Raboud; Sandra Rae; P Dailey; D Chernoff; J Todd; Brian Conway; Julio S G Montaner
Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States.
The Journal of infectious diseases 1997;176(5):1388-92.
1997: Danielle Rouleau; Brian Conway; Janet Raboud; Sandra Rae; S Fransen; A Shillington; Carlos Zala; Michael V O'Shaughnessy; Julio S G Montaner
Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.
The Journal of infectious diseases 1997;176(5):1156-60.
1997: Katherine V Heath; Hogg Robert; Joel Singer; Martin T Schechter; Michael V O'Shaughnessy; Julio S G Montaner
Physician concurrence with primary care guidelines for persons with HIV disease.
International journal of STD & AIDS 1997;8(10):609-13.
1997: Kevin J P Craib; Steffanie A Strathdee; Hogg Robert; B Leung; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection.
The Journal of infectious diseases 1997;176(3):798-800.
1997: Steffanie A Strathdee; David M Patrick; Sue Currie; Peter G A Cornelisse; Michael L Rekart; Julio S G Montaner; Martin T Schechter; Michael V O'Shaughnessy
Needle exchange is not enough: lessons from the Vancouver injecting drug use study.
AIDS (London, England) 1997;11(8):F59-65.
1997: Charles C J Carpenter; Margaret A Fischl; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Robert T Schooley; Melanie A Thompson; STEFANO VELLA; Patrick G Yeni; Paul A Volberding
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 1997;277(24):1962-9.
1997: M J Ostrow; Peter G A Cornelisse; Katherine V Heath; Kevin J P Craib; Martin T Schechter; Michael O'Shaughnessy; Julio S G Montaner; Hogg Robert
Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(2):115-20.
1997: Hogg Robert; Steffanie A Strathdee; Kevin J P Craib; Michael V O'Shaughnessy; Julio S G Montaner; Martin T Schechter
Modelling the impact of HIV disease on mortality in gay and bisexual men.
International journal of epidemiology 1997;26(3):657-61.
1997: Julio S G Montaner; Hogg Robert; Michael V O'Shaughnessy
Emerging international consensus for use of antiretroviral therapy.
Lancet 1997;349(9058):1042.
1997: Julio S G Montaner; Carlos Zala; Brian Conway; Janet Raboud; P Patenaude; Sandra Rae; Michael V O'Shaughnessy; Martin T Schechter
A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
The Journal of infectious diseases 1997;175(4):801-6.
1997: Janet Raboud; Julio S G Montaner; Sandra Rae; Brian Conway; Joel Singer; Martin T Schechter
Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome.
The Journal of infectious diseases 1997;175(3):576-82.